IperionX Limited

Fundamentals4.0
Price Action3.0
News Sentiment7.0
AI Rating
5.0

Key Drivers

  • Strong Cash
  • Negative Cash Flow
  • Financing Dependence

AI
AI Summary

5.0

IPX is evolving from a speculative critical-minerals name into a strategically validated U.S. titanium/defense platform, but the key investment issue is whether that momentum can overcome heavy cash burn and execution risk before dilution or financing pressure reset the story.

Defense
ExecutionRisk
StrategicShift‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • Strong Cash
  • Negative Cash Flow
  • Financing Dependence

IPX has strong liquidity and low debt, but ongoing losses, negative cash flow, and reliance on external financing make it a high-risk investment despite improved book value.

Liquidity
Unprofitable

Price Behavior

3.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Mid-$20s support
  • Oversold bounce

IPX remains in a short-term downtrend over the last month, but the rebound from $26.34 suggests mid-$20s support is holding while $30.40–$31.00 is the key resistance to reclaim.

downtrend
oversold
Support Level: $26.3–$26.9
Resistance Level: $30.4–$31.0

Sharp drop to $26.34 followed by a rebound to $29.73, signaling an oversold bounce

Sentiment & News

7.0

Key News Insights:

  • Asset consolidation
  • Defense scaling
  • EU progress

IperionX is accelerating Titan-area consolidation and U.S. defense titanium capacity, while Hopledo's positive CHMP opinion adds a separate regulatory upside for Parkinson's treatment.

Expansion
Defense

The updates are broadly supportive, reinforcing IperionX's strategic growth narrative and defense-linked demand visibility, with Hopledo offering an additional regulatory catalyst